Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
3.675
Zitationen
18
Autoren
2008
Jahr
Abstract
As compared with platinum-based chemotherapy plus fluorouracil alone, cetuximab plus platinum-fluorouracil chemotherapy improved overall survival when given as first-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck. (ClinicalTrials.gov number, NCT00122460.)
Ähnliche Arbeiten
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
1993 · 15.645 Zit.
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
2010 · 6.410 Zit.
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
2006 · 5.074 Zit.
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
2016 · 4.943 Zit.
Head and neck squamous cell carcinoma
2020 · 3.825 Zit.
Autoren
Institutionen
- Antwerp University Hospital(BE)
- Institut Català d'Oncologia(ES)
- Marqués de Valdecilla University Hospital(ES)
- The Maria Sklodowska-Curie National Research Institute of Oncology(PL)
- Ghent University Hospital(BE)
- Jósa András Múzeum(HU)
- Institute of Urology of the National Academy of Medical Sciences of Ukraine(UA)
- Ludwig Boltzmann Institute for Digital Health and Prevention(AT)
- Kaiser-Franz-Josef-Spital(AT)
- CEA Valduc(FR)
- Centre Antoine Lacassagne(FR)
- Alleanza Contro il Cancro(IT)
- Sumy State University(UA)
- Centre François Baclesse(LU)
- University Medical Center Hamburg-Eppendorf(DE)
- Universität Hamburg(DE)
- Merck (Germany)(DE)
- Research Institute Hospital 12 de Octubre(ES)